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Two HIV-1 isolates (CM4 and CM9) able to use alternate HIV-1 coreceptors on transfected cell lines were tested for their sensitivity to
inhibitors of HIV-1 entry on primary cells. CM4 was able to use CCR5 and Bob/GPR15 efficiently in transfected cells. The R5 isolate grew
in D32/D32 CCR5 PBMC in the absence or presence of AMD3100, a CXCR4-specific inhibitor, indicating that it uses a receptor other than
CCR5 or CXCR4 on primary cells. It was insensitive to the CCR5 entry inhibitors RANTES and PRO140, but was partially inhibited by
vMIP-1, a chemokine that binds CCR3, CCR8, GPR15 and CXCR6. The coreceptor used by this isolate on primary cells is currently
unknown. CM9 used CCR5, CXCR4, Bob/GPR15, CXCR6, CCR3, and CCR8 on transfected cells and was able to replicate in the absence
or presence of AMD3100 in D32/D32 CCR5 PBMC. It was insensitive to eotaxin, vMIP-1 and I309 when tested individually, but was
inhibited completely when vMIP-1 or I309 was combined with AMD3100. Both I309 and vMIP-1 bind CCR8, strongly suggesting that this
isolate can use CCR8 on primary cells. Collectively, these data suggest that some HIV-1 isolates can use alternate coreceptors on primary
cells, which may have implications for strategies that aim to block viral entry.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; Alternate coreceptors; CCR8; Bob/GPR15Introduction
The human immunodeficiency virus type 1 (HIV-1)
gains entry into a cell by binding to host cell surface
receptors. This interaction is a sequential process and can
be defined in three stages: namely, CD4 binding, cor-
eceptor binding and the fusion process. The two most
important coreceptors are CCR5 and CXCR4, and all HIV-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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Molecular Medicine and Haematology, University of the Witwatersrand
Medical School, Johannesburg, South Africa.1 isolates tested to date use one or both (Doms and Moore,
2000). A few rare isolates can also use other coreceptors
present on coreceptor-transfected cell-lines, including
CCR1, CCR2b, CCR3, Bob/GPR15, CXCR6 (STRL33)
and CCR8 (Cilliers et al., 2003; Deng et al., 1997; Edinger
et al., 1998; Pohlmann et al., 1999; Xiao et al., 1998).
Some of these receptors such as CXCR6 and CCR8 have
been shown to function as HIV entry coreceptors on
primary cells in vitro (Lee et al., 2000; Sharron et al.,
2000; Zhang et al., 2000, 2001). Further evidence that
some isolates can use alternate coreceptors comes from
studies where both major coreceptors are either absent or
blocked. In this regard, the use of PBMC with a 32-base
pair deletion in CCR5 (D32/D32 CCR5) in the presence of
a CXCR4 inhibitor has proven particularly useful (Aze-05) 136 – 144
Table 1
Growth of CM4 and CM9 on coreceptor transfected cell lines
Isolate Biotype Coreceptor usage (day 12 p24 ng/ml)
U87.CD4 GHOST.3
CCR5 CXCR4 Bob/GPR15 CCR3 CXCR6
CM4 R5 70 <1 65 <1 <1
CM9 R5X4 69 48 3 3 8.5
Note. Replication levels between U87.CD4 cells and GHOST.3 cells may
not be directly comparable.
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2000). Identification of alternative HIV-1 coreceptors is
hampered by the lack of suitable ligands although in some
instances chemokines have been used to provide suggestive
evidence (Willey et al., 2003). Collectively, these data
demonstrate that some rare isolates can exploit alternate
coreceptors on primary cells in vitro, although whether such
receptors are used by HIV-1 in vivo remains unclear
(Sharron et al., 2000; Willey et al., 2003; Zhang and Moore,
1999; Zhang et al., 2001).
The ability of isolates to use particular coreceptors for
viral entry can be determined by the use of inhibitors that
block specific receptors (Moore et al., 2004). Inhibitors of
CCR5 and CXCR4 have been shown to be highly effective
in vitro and are being developed for clinical use (Moore and
Doms, 2003; Seibert and Sakmar, 2004). Inhibitors binding
to CCR5 include PRO140, a monoclonal antibody (Mab)
directed at CCR5, and RANTES, a natural ligand for CCR5
(Olson et al., 1999; Wu et al., 1997). AMD3100 is a small
molecule inhibitor able to bind to CXCR4 and prevent
CXCR4-using HIV-1 isolates from infecting cells (Donzella
et al., 1998; Schols et al., 1997). Blocking CCR5 is of
particular interest as this is the coreceptor used during the
initial phases of HIV-1 infection and R5 viruses can persist
until the end stage (Douek et al., 2003; Moore et al., 2004).
The ability of some viral isolates to use alternate coreceptors
could impact on the efficacy of entry inhibitors and possibly
also HIV pathogenesis. Hence, it is relevant to identify and
characterize HIV isolates able to use alternate coreceptors
on primary cells.
A previous study reported that viral macrophage inflam-
matory protein-1 (vMIP-1), a promiscuous chemokine
expressed by Human Herpes Virus 8, could bind to a range
of coreceptors, including CCR8, GPR1, CXCR6 and to a
lesser extent Bob/GPR15 (Dairaghi et al., 1999; Willey et
al., 2003). This chemokine has been shown to prevent HIV-
1 infection of some isolates on primary cells when the major
coreceptors are absent or blocked. This suggests that vMIP-
1 might be useful in identifying alternate coreceptors that
could be used by HIV-1 isolates (Willey et al., 2003). The
aim of this study was to further investigate how two unusual
HIV-1 isolates can use alternate coreceptors on primary
cells, by using chemokines with defined receptor binding
profiles.Results
Coreceptor usage of CM4 and CM9
Two HIV-1 isolates from patients with cryptococcal
meningitis, a severe AIDS defining condition, were selected
for this study. CM9 is an HIV-1 subtype C R5X4 isolate
able to use CCR5, CXCR4, CCR3, CXCR6 and Bob/
GPR15 to replicate in transfected cell lines (Cilliers et al.,
2003) (Table 1). While the efficiency with which CM9 usedthe three minor coreceptors was considerably lower than for
the two major coreceptors (i.e. CCR5 and CXCR4), their
usage was highly reproducible on GHOST.3 cell lines.
CM4, a complex recombinant R5 virus with subtype C-like
envelope was able to use both CCR5 and Bob/GPR15 with
equal efficiency on transfected cell lines (Table 1). This
isolate was unable to use CXCR4, as judged by its inability
to replicate in U87.CD4.CXCR4 or MT-2 cells. It was
also unable to use CCR3, CXCR6 or CCR1. CCR1 was
included as a negative control for both CM4 and CM9
(Table 1).
Both CM4 and CM9 were able to replicate in D32/D32
CCR5 PBMC efficiently although CM4 replicated to higher
levels (84 ng/ml versus 10 ng/ml p24 in one representative
experiment) (see also Figs. 2 and 3). The growth seen for
CM9 in D32/D32 CCR5 PBMC is most likely related to the
ability of this isolate to use CXCR4 (Cilliers et al., 2003).
Since CM4 is unable to use CXCR4, growth in D32/D32
CCR5 PBMC must be due to an alternate receptor. Whether
CM4 is using Bob/GPR15 to enter PBMC cannot be
assessed at present as no inhibitor, including polyclonal
antibodies, or natural ligands to block this coreceptor is
available.
Use of CCR5 and CXCR4 inhibitors to determine
coreceptor use
To further define coreceptor specificity of CM9 and
CM4, specific inhibitors were used. The CCR5 inhibitors
included the anti-CCR5 Mab PRO140 and the CC-chemo-
kine RANTES. AMD3100 was also used to block CXCR4.
The assays were performed on wt/wt CCR5 PHA-stimulated
PBMC with a p24 antigen read-out on day 6. CM4 was not
inhibited by either PRO140 or RANTES at the same
concentrations that were active against other HIV-1 isolates
(Table 2) (Cilliers et al., 2003; Trkola et al., 2001). This
isolate was also insensitive to AMD3100, consistent with its
inability to use CXCR4. Hence, neither CCR5 nor CXCR4
inhibitors were effective against CM4. In contrast, CM9 was
sensitive to AMD3100 (97% inhibition on day 6, Table 2).
However, like CM4, CM9 was insensitive to the CCR5
inhibitors. Thus, the major coreceptor of preference for this
pleiotropic isolate is CXCR4 (Cilliers et al., 2003).
We next tested the ability of CM4 and CM9 to be
inhibited by the fusion inhibitor Enfuvirtide, which is not
Table 2
Effect of CCR5, CXCR4 and fusion inhibitors on CM4 and CM9
replication in (wt/wt) CCR5 PBMC
Isolate Biotype % inhibition
PRO140
(167 nM)
RANTES
(19 nM)
AMD3100
(500 nM)
Enfuvirtide
(1 Ag/ml)
CM4 R5 33 24 4 99
CM9 R5X4 36 34 97 100
T. Cilliers et al. / Virology 339 (2005) 136–144138coreceptor-specific. Both isolates were fully sensitive to
Enfuvirtide and were inhibited by >99% at 1 Ag/ml (Cilliers
et al., 2004). This demonstrates that use of an alternate
coreceptor does not radically alter the envelope-mediated
fusion process.
Env sequence analysis of CM4 and CM9 grown in different
cell lines
To determine if minor quasispecies were accounting for
multiple coreceptor use, CM4 and CM9 were grown in
different cell lines. The env genes were then sequenced and
compared to those of the original infecting strain. CM4-P2
was grown in normal donor PBMC, D32/D32 CCR5
PBMC, and GHOST.3 cells expressing Bob/GPR15. The
amino acid sequences of the expanded viruses were then
compared to the original infecting stock (CM4-P1). All
gp160 sequences from CM4-P2 grown in different cells
were identical (Fig. 1A). When these sequences were
compared to the earlier stock (CM4-P1), only a single
amino acid change in the V3 region (T300N) was noted
(Fig. 1A). Hence, the major viral population of CM4 uses
both CCR5 and Bob/GPR15 as coreceptors on transfected
cell lines as well as on D32/D32 CCR5 PBMC, suggesting
that the same envelope glycoprotein configuration can use
both CCR5 and Bob/GPR15. CM4 had a low overall charge
of +3 in the V3 loop, which is more consistent with usage of
CCR5 than of CXCR4 (Hoffman et al., 2002).
A similar analysis was done using CM9 grown in cell
lines expressing CCR5, CXCR4, CCR3, CXCR6 and Bob/
GPR15, with the resulting sequences then compared to the
original isolate grown in wt/wt PBMC. Distinct amino acid
sequence changes in gp160 were noted between the selected
populations, particularly in the V1/V2 and V3 regions of
gp120, and in the cytoplasmic tail of gp41 (Fig. 1B). Viruses
that grew in the CXCR6/Bonzo and CCR3 cell lines were
virtually identical in sequence, and most similar to the
viruses that grew in the CCR5 transfected cells. The
sequence of the virus grown in CXCR4-expressing cells
was identical to the original PBMC sequence and mostFig. 1. (A) Full-length envelope amino acid sequence alignment of CM4 grown i
CM4-P1. The regrown strain is labeled CM4-P2. CM4-P2 grown in PBMC (CM4
(CM4-Bob) is shown. The variable loops are highlighted in grey and amino aci
envelope amino acid sequence of CM9 grown in different cell lines and PBMC (C
transfected with Bob/GPR15 (CM9-Bob), U87.CD4.CCR5 (CM9-R5) and GHOST
loops are highlighted in grey and amino acid changes are shown. Dots indicate isimilar to the virus that grew out of the Bob/GPR15 cells.
Three changes were noted in the V3 crown region between
these two populations. The viruses expanded on the CXCR4
or Bob/GPR15 cells had a GPRY motif while those grown
in CCR5, CXCR6/Bonzo or CCR3 expressing cells had a
GPGY sequence. There was no difference in the overall
charge (+6) or number of amino acids in the V3 region of
the different selected populations, so no prediction about
coreceptor usage could be made from the genotype. An
insertion in the cytoplasmic tail of the gp41 region was
noted for almost all viruses grown in coreceptor-transfected
cells except for those grown in CXCR4 transfected cells
(Fig. 1B). This suggests that the original CM9 isolate
comprised at least 2 distinct populations, one that uses
CCR5, CXCR6 and CCR3 and a second that uses CXCR4
and Bob/GPR15. This mixed population may account for
the usage of at least 2 different coreceptors by this isolate.
Inhibition assays on D32/D32 CCR5 PBMC
We next explored the ability of chemokines that act as
natural ligands for alternate coreceptors to inhibit CM4 and
CM9 replication in D32/D32 CCR5 PBMC. The chemokine
vMIP-1 is a promiscuous chemokine secreted by Human
Herpes Virus 8 that binds to CCR8, GPR1, Bob/GPR15 and
CXCR6 (Dairaghi et al., 1999; Simmons et al., 2000; Willey
et al., 2003). Eotaxin is the ligand for CCR3, and I309 is
specific for CCR8. CM9 was grown in D32/D32 CCR5
PBMC in the presence of vMIP-1, I309 and eotaxin either
singly or in combination with AMD3100. It was previously
shown that CM9 could be inhibited by AMD3100 for up to 6
days on normal donor PBMC, consistent with its efficient
use of CXCR4 for entry (Cilliers et al., 2003). However, in
this study, we found that CM9 was eventually able to
replicate in the presence of AMD3100 on D32/D32 CCR5
PBMC when the assay was extended beyond 6 days (Fig.
2A). When AMD3100 was combined with eotaxin, the
natural ligand for CCR3, there was enhanced viral repli-
cation. vMIP-1 and I309 had no effect on CM9 replication
when tested individually (Fig. 2A) but when they were
combined with AMD3100, inhibition was complete (Fig.
2B). Since both I309 and vMIP-1 can bind to CCR8, CM9
may be using CCR8 to infect D32/D32 CCR5 PBMC in the
presence of AMD3100. This was confirmed when CM9 was
grown on NP2/CD4 cell lines expressing CCR8 (Fig. 4).
Replication in these cells was as efficient as growth in NP2/
CD4 cells expressing either CCR5 or CXCR4.
CM4 was tested in D32/D32 CCR5 PBMC in the absence
and presence of AMD3100, vMIP-1, I309 and CXCL16n different cell lines and PBMC. The original culture supernatant is labeled
-PBMC), D32/D32 CCR5 PBMC (CM4-D32) and GHOST.3.Bob cell line
d changes are shown. Dots indicate identical amino acids. (B) Full-length
M9-PBMC). CM9 was grown in U87.CD4.CXCR4 (CM9-X4), GHOST.3
.3.CXCR6 (CM9-CXCR6) and CCR3 (CM9-R3), respectively. The variable
dentical amino acids and dashes indicate amino acid insertions.
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Fig. 2. Inhibition of CM9 in D32/D32 CCR5 PBMC. (A) Growth curve of
CM9 in the presence of AMD3100, vMIP-1, I309, eotaxin or without
inhibitors. (B) CM9 in the presence of AMD3100 alone or in combination
with vMIP-1, I309 or eotaxin or no inhibitors. RT activity was used to
measure viral replication levels.
Fig. 3. Replication of CM4 in D32/D32 CCR5 PBMC in the presence of
AMD3100, vMIP1, I309, eotaxin, CXCL16 or without inhibitors. RT
activity was used to measure viral replication levels.
T. Cilliers et al. / Virology 339 (2005) 136–144140(Fig. 3). CXCL16 is the natural ligand for CXCR6. None of
these inhibitors had any effect on CM4 replication except
vMIP-1, which caused a delay. Hence, CM4 is using a
coreceptor other than CCR5, CXCR4, CCR8 or CXCR6 to
productively infect PBMC. Its identity is still unclear, but it
may be a vMIP-1 receptor.Discussion
The identification of HIV-1 isolates able to use corecep-
tors other than CCR5 and CXCR4 on primary cells is rare
(Lee et al., 2000; Willey et al., 2003; Zhang et al., 2000).
While the significance of alternate coreceptor usage isuncertain, the possibility that HIV-1 can expand its cellular
host range through the use of alternate coreceptors remains a
theoretical possibility especially for HIV-1 subtype C where
CXCR4 is rare. Here, we report on how two isolates, CM4
and CM9, can use alternate coreceptors to infect primary
cells. Inhibition data suggest that CCR8 and an as yet
unknown coreceptor can mediate HIV-1 entry for these two
isolates, respectively. Such isolates would be expected to be
refractory to inhibition by agents directed at CCR5 and
CXCR4.
CM4, an R5 isolate able to utilize Bob/GPR15, on
transfected cell lines was isolated from a patient with
advanced HIV disease. Its insensitivity to both CCR5 and
CXCR4 inhibitors suggested that it could use an alternate
coreceptor to infect PBMC. This receptor is apparently also
present on D32/D32 CCR5 PBMC and can support high
levels of replication. Whether CM4 is able to use Bob/
GPR15 on primary cells remains to be determined. Bob/
GPR15 is an orphan G-protein coupled receptor whose
mRNA is widely expressed in the colon, spleen, PHA
stimulated PBMC, purified T-cells and to a lesser extent in
unstimulated PBMC (Deng et al., 1997). Until a natural
ligand to Bob/GPR15 is identified, it will remain difficult to
prove that CM4 is using this receptor to enter primary cells.
In a previous study, a different batch of CM4 (CM4-P1) was
inhibited by RANTES, PRO140 and TAK779 suggesting
that entry was CCR5-dependent (Trkola et al., 2001). For
the experiments reported here, CM4 had been expanded in
PHA-stimulated PBMC to generate a high titer stock (CM4-
P2). The entry of this virus preparation was found to be
independent of CCR5, as reflected by its ability to grow in
D32/D32 CCR5 PBMC. Experiments directly comparing
the properties of the original (CM4-P1) and expanded viral
stock (CM4-P2) confirmed these findings (data not shown).
The envelope sequences of CM4-P1 and CM4-P2 showed
T. Cilliers et al. / Virology 339 (2005) 136–144 141that they were more than 99% identical (Fig. 1A). It is
unlikely that the single amino acid change T300N between
CM4-P1 and CM4-P2 is responsible for the altered
coreceptor phenotype. It is more likely that the ability of
CM4-P2 to grow in D32/D32 CCR5 PBMC is related to the
viral titer, the ability to use alternate coreceptors being only
revealed when the viral titer is high. Nevertheless, we cannot
formally rule out that the ability of CM4 to replicate in D32/
D32 CCR5 PBMC, presumably by alternate coreceptor-use,
was acquired or selected for during in vitro passage.
CM9, an R5X4 virus, was also isolated from a patient
with advanced HIV infection and it too is a pleiotropic
isolate that has a preference for CXCR4-usage (Cilliers et
al., 2003). Other studies have shown that CXCR4 is the
coreceptor of preference for most R5X4 isolates, which
explains why many are completely inhibited by AMD3100
(Yi et al., 1999). CM9 was previously shown to use alternate
coreceptors, CCR3, CXCR6 and Bob/GPR15 albeit less
efficiently than CXCR4 (Cilliers et al., 2003). In this study,
we show that in addition to using these five coreceptors,
CM9 can also use CCR8. This was confirmed using NP2/
CD4/CCR8 transfected cells, which supported CM9 repli-
cation to high levels (Fig. 4). However, the use of CCR8
appeared to be less efficient on PBMC compared to
transfected cell lines, similar to CCR5 usage by this isolate.
Thus, during the first 6 days, replication of CM9 in PBMC
was fully inhibited by AMD3100, suggesting a dominant
role of CXCR4. However, replication at later time points
was inhibited by both vMIP-1 and I309, a CCR8-specific
inhibitor, in the presence of AMD3100. Thus, it appears that
growth in the presence of AMD3100 after 6 days is due to
the ability of this isolate to use CCR8. This later use of
CCR8 may be related to expression levels of this receptor on
PBMC, which may vary in culture, or the utilization of
CCR8 by different populations in the CM9 stock, or less
efficient usage of CCR8 compared to CXCR4. CCR8 is
expressed on primary lymphocytes and at high level in the
thymus and has the ability to facilitate HIV-1 entry into
thymocytes (Baecher-Allan et al., 2001; Dieckmann et al.,
2001; Iellem et al., 2001; Lee et al., 2000). This receptor hasFig. 4. Replication of CM9 in human glioma NP-2 cell line expressing CD4 with ei
monoclonal antibody and a B-galactosidase conjugated secondary antibody. Infect
Mean of 2 independent experiments.been reported to be used by a handful of simian
immunodeficiency virus (SIV), HIV-1 and HIV-2 isolates
and is one of the more commonly used alternate coreceptors
(Horuk et al., 1998; Rucker et al., 1997). However, most of
the above studies were performed only on cell lines, raising
questions as to the significance of the findings for under-
standing replication in primary cells. Our finding that CM9
uses CCR8 on primary cells suggests that CCR8 may indeed
prove to be a significant HIV-1 coreceptor for some isolates,
a factor that may need to be taken into consideration in
clinical studies of CCR5 and CXCR4 inhibitors. Chemo-
kines that target CCR8, such as I309 may need to be
considered for drug development.
Analysis of envelope sequences from viruses grown in
PBMC and cell lines revealed that the same viral population
of CM4 was able to use CCR5, Bob/GPR15 and a
coreceptor on CCR5 deficient PBMC. In contrast, distinct
viral populations may account for some of the promiscuous
coreceptor activity of CM9. Two distinct viral populations
could be discerned in gp160 from CM9. The population
able to use CCR5, CXCR6 or CCR3 had three amino acid
changes in the V3 region and 4 amino acid changes in V2
compared to the population able to utilize CXCR4 or Bob/
GPR15. However, the population able to utilize Bob/GPR15
also had an insertion in the gp41 similar to that found in the
CCR5, CXCR6 and CCR3-using virus. This suggests that
the Bob/GPR15 utilizing envelope is distinct from all the
other populations; it even may be a recombinant between
different populations. Further studies on this virus may
provide clues as to the genetic determinants of both major
and alternate coreceptor usage. The CCR8-using virus is
likely to be a subpopulation different than the one that uses
CXCR4, as the usage of the latter coreceptor was effectively
inhibited up to day 6 in a PBMC culture. Hence, the
sequence analysis performed on CM9 grown in the different
cell lines may not be used to conclusively indicate which
viral population accounts for use of the CCR8 receptor on
D32/D32 CCR5 PBMC.
Whether it is significant that both the CM4 and the CM9
isolates were derived from patients with cryptococcalther CCR5, CXCR4 or CCR8. Cells were infected and stained with anti-p24
ed cells were stained with X-gal and the number of infectious foci counted.
T. Cilliers et al. / Virology 339 (2005) 136–144142meningitis still remains unclear. Cryptococcal meningitis is
a severe AIDS condition that arises after the immune system
has deteriorated and it is associated with high levels of viral
replication in blood and cerebrospinal fluid (Morris et al.,
1998). It is possible that when CD4 target cells are limited,
HIV-1 isolates exploit other receptors to maintain high
levels of replication. Alternatively, cryptococcal meningitis
could up-regulate other chemokine receptors or allow access
of HIV-1 to other cell populations, such as in the central
nervous system that may promote use of alternate corecep-
tors. These data may also point to the need for the use of a
combination of entry inhibitors that target different stages in
the entry cycle, such as the CD4-binding site or the fusion
process. Enfuvirtide was able to efficiently inhibit both
CM4 and CM9 strains suggesting that it is not influenced by
alternate coreceptor usage. Thus, ENF may be a useful
adjunct to coreceptor inhibitors (Tremblay et al., 2000,
2002). Collectively, these data suggest that alternate
coreceptors need to be considered when developing entry
inhibitors and that such isolates pose a threat to the clinical
use of inhibitors targeting only CCR5 and CXCR4.Materials and methods
HIV-1 viral isolates
Two previously described isolates, CM4 (99ZACM4)
and CM9 (99ZACM9) from a cohort of AIDS patients, were
selected for further analysis (Bredell et al., 2002; Cilliers et
al., 2003; Papathanasopoulos et al., 2002; Trkola et al.,
2001). CM4 was isolated in 1999 from a 34-year old male in
Johannesburg, South Africa who had advanced HIV
infection and cryptococcal meningitis. This patient had a
viral load of 163,755 HIV-1 RNA copies/ml (by bDNA
assay) and CD4 count of 47 cells/Al. CM9 was isolated in
1999 from a 30-year old female also with cryptococcal
meningitis and with a CD4 count of 24 cells/Al. No viral
load was available for this patient. Viral isolates were
generated from both patients in a previous study using
peripheral blood mononuclear cells (PBMC) cocultured
with phytohemagglutinin (PHA)-activated donor PBMC
(Cilliers et al., 2003). CM4-P1 was the first isolation
reported in a previous publication (Trkola et al., 2001),
which was later re-expanded using PHA-stimulated PBMC
and IL-2 to generate high titer stocks for these experiments
(CM4-P2). The gp160 encoding regions of both CM4-P1
and CM4-P2 were sequenced and shown to be more than
99% identical (Fig. 1A). CM4 was reported initially as an
env subtype C by HMA (Bredell et al., 2002), but
subsequent sequence analysis indicated that this virus was
a complex recombinant of at least five different subtypes
with multiple breakpoints in the env region (Papathanaso-
poulos et al., 2002). CM9 was subtype C throughout the
genome (Papathanasopoulos et al., 2002). Ethical clearance
for this study was obtained from the University of theWitwatersrand Committee for Research on Human Subjects
(Medical).
Coreceptor assays on cell lines
Both viruses were tested for their ability to replicate in
U87.CD4 cells transfected with either CCR5 or CXCR4
cells as previously described (Cilliers et al., 2003). In
addition, U87.CD4 cell lines expressing CCR1 and
GHOST.3 cell lines expressing Bob/GPR15, CCR1, CCR3
and CXCR6 were used to measure alternate coreceptor
usage. Because all GHOST.3 cell lines express endogenous
CXCR4, it was necessary to add 1.3 AM of AMD3100 to
block this activity (Zhang and Moore, 1999). Viral
replication was measured using an in-house p24 antigen
assay (Trkola et al., 2001). Increasing p24 antigen levels in
the presence of AMD3100 therefore indicated use of the
transfected coreceptor. To measure CCR8-dependent repli-
cation, we used NP2/CD4 cells expressing CCR5, CXCR4
or CCR8 (Soda et al., 1999). For this, we used immunos-
taining as previously described (Clapham et al., 1992). HIV
infected cells were fixed and stained with anti-HIV-1 p24
monoclonal antibodies (provided by the Centralised Facility
for AIDS Reagents, UK) and anti-mouse Fab’2 fragments
conjugated to h-galactosidase (Southern Biotechnology
Associates, Inc.). Infected cells stained blue on addition of
X-gal substrate (0.5 mg/ml 5-bromo-4-chloro-3-indolyl-b-
galactopyranoside; Fisher Bioreagents Inc., 3 mM potas-
sium ferrocyanide, 3 mM potassium ferricyanide and 1 mM
magnesium chloride). Groups of blue-stained cells were
regarded as foci of infection, and virus infectivity was
estimated as FFU per milliliter (FFU/ml).
D32/D32 CCR5 PBMC cell preparation
Blood was drawn from two individuals identified with
the D32/D32 CCR5 mutation and PBMC isolated and
stimulated with PHA and IL-2 as previously described
(Cilliers et al., 2003; Willey et al., 2003). AMD3100 (1 AM)
was used to inhibit entry via CXCR4.
Entry inhibitor assays
Entry inhibitor assays were performed using PHA-
stimulated PBMC from wt/wt (wild-type/wild-type) CCR5
and D32/D32 CCR5 donor cells. Cells were incubated with
the specific inhibitor for 1 h before adding 1000 50% tissue
culture infectious dose (TCID50) per ml of virus evaluated
on PBMC cultures. Assays were performed on 96 well
plates using RPMI 1640, 10% fetal calf serum and IL-2 as
previously described (Cilliers et al., 2003; Willey et al.,
2003). Inhibitors tested included the anti-CCR5 Mab
PRO140 (Progenics Pharmaceuticals, New York), chemo-
kines RANTES (PeproTech Inc., Rocky Hill, NJ), I309,
eotaxin, vMIP-I and CXCL16 (all from R&D Systems, Inc.)
and the small molecule CXCR4 antagonist, AMD3100
T. Cilliers et al. / Virology 339 (2005) 136–144 143(AnorMED Inc., Langley, Canada). Viral replication was
measured by p24 antigen production or reverse transcriptase
(RT) activity using an RT-enzyme-linked immunosorbent
assay (CavidiTech, Uppsala, Sweden). Enfuvirtide (ENF)
(American Peptide Company and Hoffmann-La Roche, Palo
Alto, Ca) was used as previously described (Cilliers et al.,
2004).
RNA extraction and amplification of the gp160 region
HIV-1 viral RNA was extracted from 200 Al of culture
supernatant from different cell lines using the MagNA Pure
LC Total Nucleic Acid Isolation Kit and automated MagNA
Pure LC Instrument (Roche Diagnostics GmbH, Mannheim,
Germany). A reverse transcription step was performed and
the cDNA was used to amplify the gp160 region with
primers as previously described (Gao et al., 1996). PCR
products were purified using the High Pure PCR Product
Purification kit (Roche Diagnostics GmbH, Mannheim,
Germany). Sequencing reactions were performed in a
MicroAmp 96 well optical reaction plate using the ABI
PRISM Big dye Terminator v3.0 Cycle Sequencing kit and
ABI PRISM 3100 automated sequencer. Sequence analysis
was performed using the Sequencher version 4.0 software
(Gene Codes Corporation). The ClustalX program was used
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